Background
==========

Gastrointestinal stromal tumors (GIST) are interlobar tumors that most often occur in the gastrointestinal tract \[[@b1-medscimonit-26-e922378]\]. They originate from the stromal cells of Cajal or their stem cell precursors. In histology, GIST consists of fusiform cells, epithelial cells, or mixed cells, that are arranged in bundles or are diffused \[[@b2-medscimonit-26-e922378]\]. GIST includes 3 types: benign, uncertain malignant potential, and malignant \[[@b1-medscimonit-26-e922378]\]. They occurs in every part of the digestive tract and are most common in the gastric stroma, accounting for about 60--70% of all cases. GIST has a broad prognostic spectrum; therefore, forecasting the prognosis of GIST patients based on clinicopathological factors is important and contributes to developing treatment plans.

The American Joint Committee on Cancer (AJCC) TNM staging system is now the most extensively used clinical tool in determining the treatment of tumor patients, but it fails to accurately reflect differences in the prognosis of various patients because the same TNM stage can have different clinical outcomes and is influenced by the assessment of clinicians \[[@b3-medscimonit-26-e922378]--[@b5-medscimonit-26-e922378]\]. The same treatment may then lead to inadequate or excessive treatment. A new type of line map has been established by Joensuu \[[@b6-medscimonit-26-e922378]\], in which the recurrence rate of patients with GIST was individually evaluated by mitotic count, tumor size, tumor location, and rupture, using magnetic resonance imaging (MRI). Compared with the TNM staging system, the model can provide a more accurate prognosis. However, age and sex can still affect the prognosis of patients, so we still need an improved system to analyze the clinical prognosis of patients with GIST.

A nomogram is considered a reliable tool for clinicians to use in predicting prognosis of patients with tumors. Compared with the AJCC system, TNM staging system can more accurately predict the survival time of patients with different tumors, and TNM staging system has been recognized in various studies \[[@b7-medscimonit-26-e922378],[@b8-medscimonit-26-e922378]\]. Research using nomograms for GIST patients alone based on population-based data have not been reported. Thus, we used the database to develop a nomogram to more precisely predict the prognosis of GIST patients.

Material and Methods
====================

Patients
--------

We obtained patient data from the SEER database, and SEER\*stat software (version 8.3.5; *<http://seer.cancer.gov/seerstat/>*) was used to screen the data. All patients were pathologically diagnosed as having GIST by morphological code (C22.0) between 1998 and 2015 from the SEER database. In accordance with the third edition of ICDO-3 for GIST (code 8936), 5381 patients with GIST were listed. Then, 4086 patients were selected from among the 5381 patients based on the following criteria: 1) no history of malignant tumor; 2) diagnosed with GIST; 3) followed up with known results; 4) detailed clinicopathological information.

Study variables
---------------

We calculated CSS and OS. For each patient, were obtained data on clinical variables, including age at diagnosis, race, sex, marital status, size, tumor grade, tumor site, SEER historical stage A, AJCC 7^th^ edition TNM stage, mitotic count, surgical management, follow-up data, and cause of death. Tumor size and age were regarded as continuous variables.

Statistical analysis
--------------------

We used the *t* test to construct nomogram baseline patient demographics. Differences between survival curves were analyzed using the log-rank test. We used univariate and multivariate Cox proportional hazards models to screen key prognostic factors. Univariate prognostic analysis was performed via log-rank and Kaplan-Meier analysis. The Cox proportional hazards model was used to obtain hazard ratios and 95% confidence intervals. A graphical nomogram was constructed from multivariate logistic regression models.

Verification of the nomogram
----------------------------

The nomogram was validated by measuring discrimination internally (training set) and externally (validation set). The discriminatory ability of every model was assessed using the concordance index (C-index). A high C-index indicates good capacity to distinguish patients with different survival conditions. SPSS 20.0 (IBM, Inc., Armonk, NY) and R software programs were used for analysis. *P*\<0.05 indicated statistical significance.

Results
=======

Demographic and pathological characteristics
--------------------------------------------

We selected 4086 patients diagnosed with GIST. Patients were separated into a training group (n=2862) and a validation (n=1224) group.

The flowchart of data selection for the training group (n=2841) and validation group (n=2781) is presented in [Figure 1](#f1-medscimonit-26-e922378){ref-type="fig"}, and patient characteristics are listed in [Table 1](#t1-medscimonit-26-e922378){ref-type="table"}. The average age was 62.67 years old, and 49.7% of patients were male. Most patients in the 2 sets were married (56.3%) and 61.6% were white. In addition to the unknown location, the most common tumor site was the fundus (15.4%), followed by the greater curvature (13.3%), lesser curvature (11.6%), body (9.2%), antrum (7.7%), cardia (7.5%), overlapping stomach lesion (6.3%), and pylorus (0.3%). The tumor size was mostly less than 5 cm (32.5%). Except for tumors in unknown locations, most tumor mitotic rates were under 5 mitoses/50 high-power field (HPF). About 67% of the patients had GIST in the localized stage, 17.4% (710) had distant stage, and 9.7% (397) had regional stage, in accordance with the SEER stage system. The median time for follow-up was 47 months in the training group and 46 months in the validation group. In the training group, 539 patients died from GIST and 327 patients died from other causes.

Nomogram construction
---------------------

In the training group, all variables in the nomogram were related to OS. [Table 2](#t2-medscimonit-26-e922378){ref-type="table"} shows the independent prognostic variables, such as age, race, sex, marital status, size, grade, tumor site, SEER historical stage A, AJCC 7^th^ TNM stage, mitotic count, and surgical management. Results of multivariate analysis identified 8 independent predictive factors: age, sex, marital status, tumor location, grade, SEER stage, tumor size, and surgical management. On the basis of these 8 variables, we built the overall survival (OS) nomogram in the training set ([Figure 2A](#f2-medscimonit-26-e922378){ref-type="fig"}). For cancer-specific survival (CSS), 9 independent predictive factors were identified: age, sex, marital status, tumor location, grade, SEER stage, tumor size, AJCC 7^th^ TNM stage, and surgical management ([Table 3](#t3-medscimonit-26-e922378){ref-type="table"}). The CSS nomogram is shown in [Figure 2B](#f2-medscimonit-26-e922378){ref-type="fig"}.

Verification of the nomogram
----------------------------

Internal and external validation was performed for the nomogram. Internal validation showed that the C-index used to predict OS and CSS nomograms was 0.778 (95% CI, 0.76--0.79) and 0.818 (95% CI, 0.80--0.84), respectively ([Table 4](#t4-medscimonit-26-e922378){ref-type="table"}), and it was consistent with the actual OS and CSS. When the validation cohort for external validation was used, the C-index was 0.794 for OS (95% CI, 0.77--0.82) and 0.843 (95% CI, 0.82--0.87) for CSS, respectively. Moreover, the nomogram in the training group, the SEER stage, and the AJCC 7^th^ TNM staging system were compared. The results showed that a nomogram for discriminating patients with GIST performed better than the SEER and TNM 7^th^ edition staging systems ([Table 4](#t4-medscimonit-26-e922378){ref-type="table"}).

Discussion
==========

Nomograms were introduced into the medical field by scholars in 1928 \[[@b9-medscimonit-26-e922378]\]. They are currently used in various cancers to evaluate the individualized prognosis \[[@b10-medscimonit-26-e922378]--[@b12-medscimonit-26-e922378]\]. Nomograms are simple and easy to use and exhibit high clinical precision. Moreover, they can elevate staging systems from the group level to the individual level and can be used to predict approximate survival under any circumstances \[[@b13-medscimonit-26-e922378]\]. In the present study, a nomogram was built to predict patient prognosis. We compared the performances of our nomogram, SEER staging, and the AJCC 7^th^ TNM stage system in the training group. Our results showed the nomogram performed better than the SEER and TNM 7^th^ staging systems.

We identified 9 factors that could predict the CSS of patients with GIST -- age, sex, marital status, tumor location, grade, SEER stage, tumor size, AJCC 7^th^ TNM stage, and surgical management -- which were consistent with previous studies \[[@b14-medscimonit-26-e922378]--[@b16-medscimonit-26-e922378]\]. Age has been regarded as a key prognostic factor in some reports and old age as an independent risk factor in other studies, indicating a reduced survival rate \[[@b17-medscimonit-26-e922378]--[@b19-medscimonit-26-e922378]\]. The older and more anxious the patients were, the less their desire to know the prognostic outcome \[[@b20-medscimonit-26-e922378]\]. Moreover, most women prefer to talk with others, whereas men usually choose deal with their cancer on their own. Some studies suggest patients communicate without reservation with family members \[[@b21-medscimonit-26-e922378]\]. Women with lower education levels were much more interested in knowing their survival rate \[[@b22-medscimonit-26-e922378]\]. Moreover, the partner can improve the prognosis \[[@b23-medscimonit-26-e922378]--[@b25-medscimonit-26-e922378]\]. Notably, the prognosis in the cardia and pylorus is better than that in the antral and other parts, which may be related to the obvious obstruction of the gastric cardia and the pylorus than that of the gastric antrum, and the earlier clinical findings.

The method used in this study has several advantages. Our nomogram is more accurate than the AJCC TNM staging system \[[@b26-medscimonit-26-e922378]\]. It effectively uses a rigorous design to provide a solid foundation for the individualized treatment of different gastric stromal tumors for clinicians. The prognoses of stage-III patients with the same TMN stage vary according to sex, age, marital status, and location of the tumor in the stomach. Prognostic differences are visually observed in the nomogram, which may result in different treatments. We calculated the scores of each individual. Discrimination and calibration indicated that the models were valid. Different nomogram-integrating anticancer treatments might further improve survival prediction. From the nomogram, 9 variables were obtained, which provided information on GIST and could also determine the correlation of developed tools. Although the model was built on the basis of a large population-based cohort and could increase the accuracy of the nomogram, the SEER database contained no data on chemotherapy and other targeted therapy, which could lead to bias. In addition, many possible predictive variables were excluded, such as pain, C-reactive protein, albumin, and molecular markers. Therefore, the use of this model, combined with tumor markers and other indicators, may more accurately predict patient prognosis.

Conclusions
===========

The nomogram in our study was constructed by using statistically significant prognostic factors, including age, sex, marital status, tumor location, grade, SEER stage, tumor size, and surgical management. It performs better than the SEER and TNM 7^th^ edition staging systems in discriminating patients with GIST. Our nomogram can more precisely predict the prognosis of GIST patients, and has clinical significance as it can guide individualized treatment.

**Source of support:** Departmental sources
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###### 

Patient demographics and pathological characteristics.

  Variables                       All patients (n=4086)   Training set (n=2862)   Validation set (n=1224)                 
  ------------------------------- ----------------------- ----------------------- ------------------------- ------ ------ ------
  Age                                                                                                                     
   \<50                           718                     17.6                    497                       17.4   221    18.1
   50--64                         1429                    35                      1007                      35.2   422    34.5
   65--79                         1481                    36.2                    1031                      36     450    36.8
   ≥80                            458                     11.2                    327                       11.4   131    10.7
  Sex                                                                                                                     
   Female                         2054                    50.3                    1436                      50.2   618    50.5
   Male                           2032                    49.7                    1426                      49.8   606    49.5
  Race                                                                                                                    
   White                          2517                    61.6                    1741                      60.8   776    63.4
   Black                          976                     23.9                    693                       24.2   283    23.1
   Other/unknown                  593                     14.5                    428                       15     165    13.5
  Marital status                                                                                                          
   Married                        2301                    56.3                    1618                      56.5   683    55.8
   Single                         685                     16.8                    473                       16.5   212    17.3
   Unknown                        1100                    26.9                    771                       26.9   329    26.9
  Tumor site                                                                                                              
   Cardia                         308                     7.5                     220                       7.7    88     7.2
   Fundus                         630                     15.4                    418                       14.6   212    17.3
   Body                           376                     9.2                     278                       9.7    98     8
   Antrum                         314                     7.7                     213                       7.4    101    8.3
   Pylorus                        12                      0.3                     9                         0.3    3      0.2
   Lesser curvature               474                     11.6                    327                       11.4   147    12
   Greater curvature              545                     13.3                    383                       13.4   162    13.2
   Overlapping stomach lesion     257                     6.3                     193                       6.7    64     5.2
   Stomach NOS                    1170                    28.6                    821                       28.7   349    28.5
  Tumour size                                                                                                             
   ≤5                             1329                    32.5                    926                       32.4   403    33
   5.1--10                        1016                    24.9                    703                       24.6   313    25.6
   \>10                           787                     19.3                    538                       18.8   249    20.3
   Unknown                        954                     23.3                    695                       24.3   259    21.2
  Mitotic index, mitoses/50 HPF                                                                                           
   \<5                            1237                    30.3                    849                       29.7   388    31.7
   5--10                          170                     4.2                     129                       4.5    41     3.3
   \>10                           174                     4.3                     123                       4.3    51     4.2
   Unknown                        2505                    61.3                    1761                      61.5   744    60.8
  Grade                                                                                                                   
   I                              514                     12.6                    357                       12.5   157    12.8
   II                             401                     9.8                     280                       9.8    121    9.9
   III                            163                     4                       118                       4.1    45     3.7
   IV                             240                     5.9                     162                       5.7    78     6.4
   Unknown                        2768                    67.7                    1945                      68     823    67.2
  Stage                                                                                                                   
   Localized                      2739                    67                      1904                      66.5   835    68.2
   Regional                       397                     9.7                     296                       10.3   101    8.3
   Distant                        710                     17.4                    499                       17.4   211    17.2
   Unknown                        240                     5.9                     163                       5.7    77     6.3
  Surgery                                                                                                                 
   Performed                      3371                    82.5                    2361                      82.5   1010   82.5
   None                           715                     17.5                    501                       17.5   214    17.5

###### 

Univariate and multivariate analyses of overall survival in the training set.

  Variable                       Univariate analysis   Multivariate analysis   
  ------------------------------ --------------------- ----------------------- ---------
  Age                            \<0.001                                       
   \<50                                                Reference               
   50--64                                              1.328 (1.050--1.680)    0.018
   65--79                                              2.450 (1.954--3.070)    \<0.001
   ≥80                                                 4.859 (3.749--6.299)    \<0.001
  Sex                            \<0.001                                       
   Female                                              Reference               
   Male                                                1.408 (1.221--1.624)    \<0.001
  Race                           \<0.001                                       
   White                                               Reference               
   Black                                               1.107 (0.942--1.301)    0.218
   Other/unknown                                       0.807 (0.652--0.999)    0.049
  Marital status                 \<0.001                                       
   Married                                             Reference               
   Single                                              1.419 (1.167--1.724)    \<0.001
   Unknown                                             1.059 (0.896--1.253)    0.5
  Tumor site                     \<0.001                                       
   Cardia                                              Reference               
   Fundus                                              0.682 (0.516--0.901)    0.007
   Body                                                0.734 (0.540--0.997)    0.048
   Antrum                                              0.537 (0.372--0.774)    \<0.001
   Pylorus                                             2.852 (1.037--7.843)    0.042
   Lesser curvature                                    0.755 (0.551--1.034)    0.079
   Greater curvature                                   0.735 (0.551--0.981)    0.036
   Overlapping stomach lesion                          0.874 (0.629--1.212)    0.418
   Stomach NOS                                         0.789 (0.618--1.007)    0.057
  Tumour size                    \<0.001                                       
   ≤5                                                  Reference               
   5.1--10                                             1.230 (0.964--1.568)    0.096
   \>10                                                1.462 (1.124--1.903)    0.005
   Unknown                                             1.850 (1.472--2.326)    \<0.001
  Mitotic index,mitoses/50 HPF   \<0.001                                       
   \<5                                                 Reference               
   5--10                                               0.902 (0.469--1.736)    0.758
   \>10                                                1.107 (0.586--2.088)    0.755
   Unknown                                             1.109 (0.716--1.717)    0.643
  Grade                          \<0.001                                       
   I                                                   Reference               
   II                                                  1.158 (0.760--1.766)    0.494
   III                                                 2.083 (1.322--3.283)    0.002
   IV                                                  1.823 (1.270--2.754)    0.004
   Unknown                                             1.132 (0.802--1.596)    0.481
  Stage                          \<0.001                                       
   Localized                                           Reference               
   Regional                                            1.464 (1.181--1.815)    \<0.001
   Distant                                             2.339 (1.931--2.832)    \<0.001
   Unknown                                             1.264 (0.969--1.649)    0.084
  AJCC 7^th^ stage               \<0.001                                       
   I                                                   Reference               
   II                                                  0.603 (0.282--1.289)    0.192
   III                                                 1.504 (0.684--3.306)    0.31
   IV                                                  1.069 (0.612--1.845)    0.812
   Unknown                                             1.270 (0.734--2.196)    0.392
  Surgery                        \<0.001                                       
   None                                                Reference               
   Performed                                           0.435 (0.365--0.518)    \<0.001

###### 

Univariate and multivariate analyses of CSS in the training set.

  Variable                        Univariate analysis   Multivariate analysis   
  ------------------------------- --------------------- ----------------------- ---------
  Age                             \<0.001                                       
   \<50                                                 Reference               
   50--64                                               1.101 (0.853--1.421)    0.461
   65--79                                               1.682 (1.300--2.175)    \<0.001
   ≥80                                                  3.001 (2.193--4.106)    \<0.001
  Sex                             \<0.001                                       
   Female                                               Reference               
   Male                                                 1.286 (1.073--1.543)    0.007
  Race                            0.003                                         
   White                                                Reference               
   Black                                                1.105 (0.903--1.353)    0.332
   Other/unknown                                        0.866 (0.665--1.128)    0.286
  Marital status                  0.001                                         
   Married                                              Reference               
   Single                                               1.382 (1.093--1.749)    0.007
   Unknown                                              0.969 (0.778--1.208)    0.781
  Tumor site                      \<0.001                                       
   Cardia                                               Reference               
   Fundus                                               0.621 (0.432--0.895)    0.01
   Body                                                 0.724 (0.488--1.074)    0.108
   Antrum                                               0.542 (0.334--0.879)    0.013
   Pylorus                                              2.589 (0.619--10.827)   0.193
   Lesser curvature                                     0.729 (0.481--1.104)    0.136
   Greater curvature                                    0.720 (0.495--1.046)    0.085
   Overlapping stomach lesion                           0.873 (0.578--1.318)    0.519
   Stomach NOS                                          0.770 (0.563--1.052)    0.101
  Tumour size                     \<0.001                                       
   ≤5                                                   Reference               
   5.1--10                                              1.285 (0.899--1.836)    0.169
   \>10                                                 1.712 (1.200--2.445)    0.003
   Unknown                                              2.380 (1.715--3.304)    \<0.001
  Mitotic index, mitoses/50 HPF   \<0.001                                       
   \<5                                                  Reference               
   5--10                                                0.877 (0.397--1.940)    0.747
   \>10                                                 0.968 (0.446--2.096)    0.933
   Unknown                                              1.108 (0.656--1.872)    0.702
  Grade                           \<0.001                                       
   I                                                    Reference               
   II                                                   1.467 (0.719--2.990)    0.292
   III                                                  2.961 (1.478--5.931)    \<0.001
   IV                                                   3.399 (1.797--6.429)    \<0.001
   Unknown                                              1.712 (0.946--3.099)    0.076
  Stage                           \<0.001                                       
   Localized                                            Reference               
   Regional                                             1.917 (1.469--2.504)    \<0.001
   Distant                                              3.103 (2.438--3.949)    \<0.001
   Unknown                                              1.360 (0.959--1.928)    0.085
  AJCC 7^th^ stage                \<0.001                                       
   I                                                    Reference               
   II                                                   1.929 (0.602--6.179)    0.269
   III                                                  5.485 (1.663--18.094)   0.005
   IV                                                   3.101 (1.182--8.133)    0.021
   Unknown                                              4.062 (1.538--10.730)   0.005
  Surgery                         \<0.001                                       
   None                                                 Reference               
   Performed                                            0.402 (0.324--0.499)    \<0.001

###### 

Discrimination efficiency.

                         Training cohort   Validation cohort           
  ---------------------- ----------------- ------------------- ------- ------------
  Nomogram               0.778             0.76--0.79          0.794   0.77--0.82
  SEER stage             0.665             0.65--0.68          0.668   0.64--0.70
  AJCC TNM 7^th^ stage   0.588             0.57--0.60          0.6     0.57--0.63
  Nomogram               0.818             0.80--0.84          0.843   0.82--0.87
  SEER stage             0.722             0.70--0.74          0.737   0.70--0.77
  AJCC TNM 7^th^ stage   0.625             0.61--0.64          0.634   0.61--0.66
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